{"id":"fludarabine-monophosphate-melphalan-bortezomib","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1096882","moleculeType":"Small molecule","molecularWeight":"365.21"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fludarabine monophosphate works by incorporating into DNA and interfering with DNA synthesis, leading to cell death. Melphalan works by cross-linking DNA, causing DNA damage and cell death. Bortezomib works by blocking the proteasome, a complex that degrades proteins, leading to an accumulation of defective proteins and cell death.","oneSentence":"Fludarabine monophosphate is a purine analog that interferes with DNA synthesis, melphalan is an alkylating agent that cross-links DNA, and Bortezomib is a proteasome inhibitor that blocks protein degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:53.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT02440464","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT01453101","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-09","conditions":"Multiple Myeloma","enrollment":54},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00793572","phase":"PHASE2","title":"Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-10","conditions":"Refractory Plasma Cell Myeloma","enrollment":32},{"nctId":"NCT00948922","phase":"PHASE2","title":"Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-06-18","conditions":"Multiple Myeloma","enrollment":124},{"nctId":"NCT04008888","phase":"NA","title":"a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-01-05","conditions":"Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma","enrollment":50},{"nctId":"NCT00564200","phase":"PHASE2","title":"MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-11","conditions":"Multiple Myeloma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fludara","Phenylalanine Mustard","Velcade"],"phase":"phase_2","status":"active","brandName":"Fludarabine monophosphate, melphalan, Bortezomib","genericName":"Fludarabine monophosphate, melphalan, Bortezomib","companyName":"Hackensack Meridian Health","companyId":"hackensack-meridian-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine monophosphate is a purine analog that interferes with DNA synthesis, melphalan is an alkylating agent that cross-links DNA, and Bortezomib is a proteasome inhibitor that blocks protein degradation. Used for Relapsed or refractory multiple myeloma, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}